Archimed will acquire ESPERION THERAPEUTICS INC for up to $1.1B, taking the drugmaker private. The $3.16 per share cash offer represents a 58% premium over the last closing price. This buyout provides an immediate exit for shareholders after the stock rose 55% in Friday morning trading.

Cash Premiums and Sales Targets